Pinterest • The world’s catalogue of ideas

Sun Pharmaceutical Industries Ltd has informed BSE that one of the Company's wholly-owned subsidiaries has voluntarily

Sun Pharmaceutical Industries Ltd has announced the following consolidated results for the quarter ended June 30, 2016:

Sun Pharmaceutical Industries Ltd announced today the successful completion of its acquisition of InSite Vision Incorporated.

Here’s a round-up of the stories thus far: Reuters: FDA bans imports from Sun Pharma plant in India crackdown The U.S. Food and Drug Administration (FDA) has banned imports from Indian generic drugmaker Sun Pharmaceutical Industries Ltd’s plant at Karkhadi in the western state of Gujarat, in the latest quality blow for India’s drug sector. …

Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec , Imatinib Mesylate tablets 100mg and 400mg Imatinib Mesylate tablets,

Chennai: Drug major Sun Pharmaceutical Industries Ltd on Monday announced the launch of ready-to-administer cancer drug Gemcitabine InfuSMART in Europe. In a statement, the company said InfuSMART is a technology in which oncology/cancer products were developed in a ready-to-administer bag. "Until now, compounding of oncology products was done at compounding centres or compounded in hospi.. Read More

Sun Pharmaceutical Industries Ltd’s southward journey continues for yet another trading session. The scrip is currently trading 1.3% lower at Rs. 709.15 on BSE, which is a 16-month low level. - See more at:

Sun Pharmaceuticals Industries Limited has announced that Sun Pharmaceutical Industries Ltd, along with its subsidiary ( Sun Pharma) has entered into a settlement agreement with Acorda Therapeutics, Inc. - See more at:

heart 1

Sun Pharmaceutical Industries Ltd ended 2.8% higher at Rs. 777.3 after the US drug regulator gave a green signal to the company’s generic Gleevec drug.

Sun Pharma raises Rs 1,000 cr via NCDs

Drug major Sun Pharmaceutical Industries has said it has raised Rs 1,000 crore through issuance of non-convertible debentures (NCDs) on private placement basis. "Sun Pharma Laboratories Ltd, a whol...

pin 1